MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult patients with schizophrenia, is now available by prescription in pharmacies across the United States and Puerto Rico. LATUDA was approved by the U.S. Food and Drug Administration (FDA) on October 28, 2010 and is available in 40 mg and 80 mg tablet strengths.
